BRIEF-Helix Biopharm says trial steering committee made recommendation to initiate phase II component of LDOS002 study

Thu Apr 21, 2016 5:44am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

April 21 (Reuters) - Helix Biopharma:

* Trial Steering Committee Recommends Initiation Of Phase II L DOS47 study in non-small cell lung cancer

* Says trial steering committee recommendation to initiate phase II component of LDOS002 study

Source text for Eikon:

Further company coverage: (Bengaluru Newsroom)